Oversulfated chondroitin sulfate inhibits the complement classical pathway by potentiating C1 inhibitor.
Oversulfated chondroitin sulfate (OSCS) has become the subject of multidisciplinary investigation as a non-traditional contaminant in the heparin therapeutic preparations that were linked to severe adverse events. In this study, it was found that OSCS inhibited complement fixation on bacteria and bacterial lysis mediated by the complement classical pathway. The inhibition of complement by OSCS is not due to interference with antibody/antigen interaction or due to consumption of C3 associated with FXII-dependent contact system activation. However, OSCS complement inhibition is dependent on C1 inhibitor (C1inh) since the depletion of C1inh from either normal or FXII-deficient complement plasma prevents OSCS inhibition of complement activity. Surface plasmon resonance measurements revealed that immobilized C1inhibitor bound greater than 5-fold more C1s in the presence of OSCS than in presence of heparin. Although heparin can also inhibit complement, OSCS and OSCS contaminated heparin are more potent inhibitors of complement. Furthermore, polysulfated glycosaminoglycan (PSGAG), an anti-inflammatory veterinary medicine with a similar structure to OSCS, also inhibited complement in the plasma of dogs and farm animals. This study provides a new insight that in addition to the FXII-dependent activation of contact system, oversulfated and polysulfated chondroitin-sulfate can inhibit complement activity by potentiating the classical complement pathway regulator C1inh. This effect on C1inh may play a role in inhibiting inflammation as well as impacting bacterial clearance.
Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Zhao-Hua
ZH
Zhou
Mohsen
M
Rajabi
Trina
T
Chen
Elena
E
Karnaukhova
Steven
S
Kozlowski
D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000737:chemistry; D001777:Blood Coagulation / Q000187:drug effects; D002809:Chondroitin Sulfates / Q000737:chemistry / Q000494:pharmacology*; D003172:Complement C1 / Q000037:antagonists & inhibitors / Q000737:chemistry; D050718:Complement C1 Inhibitor Protein / Q000737:chemistry / Q000378:metabolism*; D004285:Dogs; D004340:Drug Contamination; D005174:Factor XII / Q000737:chemistry / Q000187:drug effects; D006493:Heparin / Q000009:adverse effects / Q000737:chemistry*; D010949:Plasma / Q000737:chemistry / Q000378:metabolism
D000925:Anticoagulants; D003172:Complement C1; D050718:Complement C1 Inhibitor Protein; D005174:Factor XII; D006493:Heparin; D002809:Chondroitin Sulfates